Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.

Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS.

JCI Insight. 2018 Jul 25;3(14). pii: 120594. doi: 10.1172/jci.insight.120594. [Epub ahead of print]

2.

Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.

Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA.

Cancer Res. 2017 Sep 15;77(18):4934-4946. doi: 10.1158/0008-5472.CAN-16-3541. Epub 2017 Jul 20.

PMID:
28729413
3.

Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells.

Fettig LM, McGinn O, Finlay-Schultz J, LaBarbera DV, Nordeen SK, Sartorius CA.

Oncogene. 2017 Nov 2;36(44):6074-6084. doi: 10.1038/onc.2017.204. Epub 2017 Jul 10.

4.

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer.

Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR.

Front Oncol. 2017 May 15;7:94. doi: 10.3389/fonc.2017.00094. eCollection 2017.

5.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

6.

The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.

Wellberg EA, Johnson S, Finlay-Schultz J, Lewis AS, Terrell KL, Sartorius CA, Abel ED, Muller WJ, Anderson SM.

Breast Cancer Res. 2016 Dec 20;18(1):131. doi: 10.1186/s13058-016-0795-0.

7.

Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies.

Hanna C, Kwok L, Finlay-Schultz J, Sartorius CA, Cittelly DM.

J Vis Exp. 2016 Nov 30;(117). doi: 10.3791/54944.

8.

Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Matthews SB, Sartorius CA.

Horm Cancer. 2017 Feb;8(1):4-15. doi: 10.1007/s12672-016-0275-0. Epub 2016 Oct 28. Review.

9.

Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.

Brechbuhl HM, Finlay-Schultz J, Yamamoto TM, Gillen AE, Cittelly DM, Tan AC, Sams SB, Pillai MM, Elias AD, Robinson WA, Sartorius CA, Kabos P.

Clin Cancer Res. 2017 Apr 1;23(7):1710-1721. doi: 10.1158/1078-0432.CCR-15-2851. Epub 2016 Oct 4.

10.

Cooperative Dynamics of AR and ER Activity in Breast Cancer.

D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK.

Mol Cancer Res. 2016 Nov;14(11):1054-1067. Epub 2016 Aug 26.

11.

Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.

Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius CA, Spillman MA.

Gynecol Oncol. 2016 Mar;140(3):518-26. doi: 10.1016/j.ygyno.2015.12.022. Epub 2015 Dec 28.

PMID:
26731726
12.

The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.

Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL.

Nat Commun. 2015 Dec 21;6:10077. doi: 10.1038/ncomms10077.

13.

Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer.

Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA.

Int J Gynecol Cancer. 2015 Nov;25(9):1565-73. doi: 10.1097/IGC.0000000000000553.

14.

Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism.

Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM.

Oncogene. 2016 Jun 2;35(22):2881-92. doi: 10.1038/onc.2015.353. Epub 2015 Sep 28.

15.

Steroid hormones, steroid receptors, and breast cancer stem cells.

Finlay-Schultz J, Sartorius CA.

J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):39-50. doi: 10.1007/s10911-015-9340-5. Epub 2015 Aug 12. Review.

16.

p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.

Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR.

Mol Cancer Ther. 2015 May;14(5):1117-29. doi: 10.1158/1535-7163.MCT-14-0538-T. Epub 2015 Mar 10.

17.

Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.

Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA.

Oncogene. 2015 Jul;34(28):3676-87. doi: 10.1038/onc.2014.298. Epub 2014 Sep 22.

18.

Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery.

Reid BG, Jerjian T, Patel P, Zhou Q, Yoo BH, Kabos P, Sartorius CA, Labarbera DV.

Curr Chem Genom Transl Med. 2014 Feb 7;8(Suppl 1):27-35. doi: 10.2174/2213988501408010027. eCollection 2014.

19.

Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.

Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA.

Horm Cancer. 2013 Feb;4(1):36-49. doi: 10.1007/s12672-012-0127-5. Epub 2012 Nov 27.

20.

Canid progesterone receptors lack activation function 3 domain-dependent activity.

Gracanin A, van Wolferen ME, Sartorius CA, Brenkman AB, Schoonen WG, Mol JA.

Endocrinology. 2012 Dec;153(12):6104-13. doi: 10.1210/en.2012-1793. Epub 2012 Oct 5.

PMID:
23041671
21.

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA.

Breast Cancer Res Treat. 2012 Sep;135(2):415-32. doi: 10.1007/s10549-012-2164-8. Epub 2012 Jul 24.

22.

Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.

Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL.

Breast Cancer Res. 2012 Jul 5;14(4):R100. doi: 10.1186/bcr3219.

23.

A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.

Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, LaBarbera DV.

J Biomol Screen. 2012 Oct;17(9):1211-20. Epub 2012 Jun 29.

24.

Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.

Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK.

Oncogene. 2013 May 16;32(20):2555-64. doi: 10.1038/onc.2012.275. Epub 2012 Jul 2.

25.

Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.

Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkilä P, Perou CM, Horwitz KB.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2742-7. doi: 10.1073/pnas.1106509108. Epub 2011 Oct 3.

26.

Progesterone regulation of stem and progenitor cells in normal and malignant breast.

Axlund SD, Sartorius CA.

Mol Cell Endocrinol. 2012 Jun 24;357(1-2):71-9. doi: 10.1016/j.mce.2011.09.021. Epub 2011 Sep 16. Review.

27.

Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis.

Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB.

Cancer Res. 2010 Nov 1;70(21):8927-36. doi: 10.1158/0008-5472.CAN-10-1238. Epub 2010 Oct 19.

28.

Ovarian steroid hormones: what's hot in the stem cell pool?

Cittelly DM, Richer JK, Sartorius CA.

Breast Cancer Res. 2010;12(4):309. doi: 10.1186/bcr2627. Epub 2010 Aug 31.

29.

Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.

Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA.

Breast Cancer Res Treat. 2011 Jul;128(1):45-55. doi: 10.1007/s10549-010-1078-6. Epub 2010 Jul 28.

30.

Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis.

Horwitz KB, Sartorius CA.

J Clin Endocrinol Metab. 2008 Sep;93(9):3295-8. doi: 10.1210/jc.2008-0938. Epub 2008 Jul 22.

31.

Progesterone receptor action: translating studies in breast cancer models to clinical insights.

Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM.

Adv Exp Med Biol. 2008;630:94-111. Review.

PMID:
18637487
32.

Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.

Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA.

Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5774-9. doi: 10.1073/pnas.0706216105. Epub 2008 Apr 7.

33.

Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis.

Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, Horwitz KB.

Cancer Res. 2007 Nov 1;67(21):10582-91.

34.
35.

Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.

Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB.

Cancer Res. 2006 Sep 15;66(18):9308-15.

36.

Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B.

Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB.

Mol Endocrinol. 2006 Nov;20(11):2656-70. Epub 2006 Jun 8.

PMID:
16762974
37.

Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.

Sartorius CA, Harvell DM, Shen T, Horwitz KB.

Cancer Res. 2005 Nov 1;65(21):9779-88.

38.

Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture.

Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB.

Endocrinology. 2006 Feb;147(2):700-13. Epub 2005 Oct 20.

PMID:
16239301
39.

Expression profiling of human breast cancers and gene regulation by progesterone receptors.

Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB.

J Mammary Gland Biol Neoplasia. 2003 Jul;8(3):257-68. Review.

PMID:
14973372
40.

Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure.

Takimoto GS, Tung L, Abdel-Hafiz H, Abel MG, Sartorius CA, Richer JK, Jacobsen BM, Bain DL, Horwitz KB.

J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):209-19.

PMID:
12943706
41.

Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts.

Sartorius CA, Shen T, Horwitz KB.

Breast Cancer Res Treat. 2003 Jun;79(3):287-99.

PMID:
12846413
42.

Different pathways regulate expression of the skeletal myosin heavy chain genes.

Allen DL, Sartorius CA, Sycuro LK, Leinwand LA.

J Biol Chem. 2001 Nov 23;276(47):43524-33. Epub 2001 Sep 10.

43.

Mapping the unique activation function 3 in the progesterone B-receptor upstream segment. Two LXXLL motifs and a tryptophan residue are required for activity.

Tung L, Shen T, Abel MG, Powell RL, Takimoto GS, Sartorius CA, Horwitz KB.

J Biol Chem. 2001 Oct 26;276(43):39843-51. Epub 2001 Aug 23.

44.
45.

Myosin heavy chains IIa and IId are functionally distinct in the mouse.

Sartorius CA, Lu BD, Acakpo-Satchivi L, Jacobsen RP, Byrnes WC, Leinwand LA.

J Cell Biol. 1998 May 18;141(4):943-53.

46.

Surprises with antiprogestins: novel mechanisms of progesterone receptor action.

Horwitz KB, Sartorius CA, Hovland AR, Jackson TA, Groshong SD, Tung L, Takimoto GS.

Ciba Found Symp. 1995;191:235-49; discussion 250-3. Review.

PMID:
8582200
47.

A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform.

Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB.

Mol Endocrinol. 1994 Oct;8(10):1347-60.

PMID:
7854352
48.
49.

Supplemental Content

Loading ...
Support Center